Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT?

Robin Prestwich a,⇑, Chirag Patel b, Andrew Scarsbrook b, Viv Cosgrove c, Emma Thomas a, Di Gilson a, David Bird c

Abstract

Involved site lymphoma radiotherapy clinical target volumes (CTV) require expansion in the absence of treatment-position pre-chemotherapy PET-CT. This prospective imaging study evaluates CTV contouring for axillary lymphoma using diagnostic imaging compared with co-registered treatment-position PET-CT. Generous expansion axially and cranio-caudally is required to encompass pre-chemotherapy disease without treatment-position pre-chemotherapy PET-CT.

© 2018 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

There has been considerable progress in reducing radiotherapy target volumes in lymphoma patients to minimise late complications whilst maintaining local control [1–3]. The concept of involved node radiotherapy (INRT) was developed with the aim of treating only prior sites of lymph node involvement [1]. INRT requires the acquisition of a pre-chemotherapy Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography – computed tomography (PET-CT) scan in the radiotherapy treatment position with the use of the relevant radiotherapy immobilisation devices and subsequent co-registration to the post-chemotherapy radiotherapy planning CT scan. However, few centres routinely acquire a pre-chemotherapy FDG PET-CT in the potential radiotherapy treatment position [4]. The concept of involved site radiotherapy (ISRT) has been developed by the International Lymphoma Radiotherapy Oncology Group (ILROG) [2,3]. The ILROG guidelines provide guidance on delineating a clinical target volume (CTV) to encompass pre-chemotherapy disease, modified to anatomical boundaries, with an additional expansion to account for any uncertainty in defining pre-chemotherapy disease (including the quality and position of pre-chemotherapy imaging, response to chemotherapy, knowledge of potential subclinical extent, volume changes since imaging, proximity to critical structures) with modification to anatomical boundaries. This CTV expansion is essentially based upon clinical judgement [4]. The UK National Cancer Research Institute Lymphoma Radiotherapy Group [5] also developed ISRT guidelines and attempted to quantify the required CTV expansion specifying 1.5 cm cranio-caudally in the direction of lymphatic spread with no axial expansion.

There is little data to guide the necessary CTV expansion to account for the absence of pre-chemotherapy imaging in the radiotherapy position. We have performed a prospective imaging study aiming to quantify the required CTV expansion, and have previously reported results for patients requiring head and neck radiotherapy [6]. Axillary radiotherapy is a less common scenario although CTV delineation is particularly challenging compared with the head and neck region, with differences in arm position between scans and less well defined anatomical landmarks. Here, we report data from patients in our imaging study with axillary nodal disease.
2. Methods

2.1. Study outline

This is a report on patients with axillary nodal disease included within a prospective single centre imaging study. Inclusion criteria were: age ≥18 years old, histologically proven Hodgkin’s Lymphoma (HL) or high grade non-Hodgkins Lymphoma (NHL), World Health Organization Performance status 0–2, Ann Arbor Stage I/II disease based upon clinical examination and any radiology investigations previously performed, residual disease in situ after biopsy, PET-CT staging not yet performed, clinical decision that sequential chemotherapy and radiotherapy will be the recommended treatment if stage I/II disease is confirmed. The aim of this study was to register imaging, no additional CTV expansion was undertaken on subsequent PET-CT staging. This study was approved by the Research Ethics Committee. Trial registration: ISRCTN Registry: ISRCTN46587767.

A total of 19 patients provided written informed consent and were recruited between October 2013 and January 2016; 3 of the patients who subsequently received chemotherapy and radiotherapy had axillary nodal disease.

2.2. PET-CT imaging

A 5-point thermoplastic immobilisation mask was fabricated prior to PET-CT acquisition, with arms by sides. FDG PET-CT imaging was performed as previously described [6]. A diagnostic half-body PET-CT with arms up on a soft head support was initially performed 60 min following a 400 MBq injection of FDG intravenously; if patients were not able to tolerate the arms up position an arms down position was used. A dedicated contrast-enhanced PET-CT of the axillary region was then acquired with the immobilization mask in place with a radiotherapy head rest, arms down (3–4 bed positions, 2 min per bed position).

2.3. Radiotherapy CT planning scan

The thermoplastic mask fabricated for the pre-chemotherapy PET-CT scan was fitted to assess whether the fit remained optimal. If this was not the case, a new thermoplastic mask was made attempting to maintain a similar neck position. The CT planning scan was acquired with intravenous contrast and 2 or 3 mm slice thickness (dependent upon institutional protocols at the time).

2.4. CTV contouring

Contouring was performed by an experienced radiation oncologist with access to clinical data and diagnostic imaging. To minimise recall, a minimum two week interval was mandated prior to contouring for each individual patient using different methods.

2.5. Contouring using side-by-side assessment of PET-CT acquired in diagnostic position (CTV<sub>diagPET</sub>)

A post-chemotherapy CTV aiming to encompass initially involved lymphoma tissue was contoured using the pre-chemotherapy diagnostic position PET-CT by side-by-side assessment (blinded to treatment position PET-CT), taking into account changes in lymphoma volume and anatomical changes, whilst accounting for anatomical boundaries. To allow quantification of the ‘errors’ introduced by contouring without optimal co-registered imaging, no additional CTV expansion was undertaken (CTV<sub>diagPET</sub>).

2.6. Contouring using co-registration of PET-CT acquired in radiotherapy position to planning CT scan (CTV<sub>INRT</sub>)

Contouring was performed according to the principles of the ILROG guidelines [2,3] and as previously described [6] (CTV<sub>INRT</sub>). The contrast-enhanced pre-chemotherapy PET-CT acquired in the radiotherapy position was used to manually contour a gross tumour volume (GTV). Manual rigid registration was undertaken matching to the chest wall and local soft-tissue in the region of the delineated GTV using Mirada RTx v1.4 software (Mirada Medical, Oxford, UK).

3. Data analysis

3.1. Assessment of superior and inferior CTV extent

Distance between the superior slices of the CTV<sub>INRT</sub> and CTV<sub>diagPET</sub> was recorded. Distance was similarly recorded for inferior slices.

3.2. Positional analysis

Positional metrics were used to compare CTVs in the axial plane as previously described [6,7]. The most superior and inferior overlapping slices of the CTVs (CTV<sub>INRT</sub> and CTV<sub>diagPET</sub>) were defined as the limits of the volume, excluding differences in the superior-inferior CTV length from influencing positional metrics. Positional metrics were calculated using ImSimQA software (v3.1.5, OSL, Shrewsbury, UK): Mean distance to conformity (MDC); Centre of gravity distance (CGD); DICE index; conformity index (CI); sensitivity index (Se. Idx). For the CTV<sub>INRT</sub> and CTV<sub>diagPET</sub> axial plane comparison, the Se. Idx. calculated the overlap between CTV<sub>diagPET</sub> and CTV<sub>INRT</sub> as a percentage of the volume of CTV<sub>INRT</sub>.

3.3. Statistics

Linear mixed effects models were used to determine the significance of the differences between CTV<sub>INRT</sub> and CTV<sub>diagPET</sub> [8]. A significant p-value was considered to be p < 0.05.

4. Results

3 patients who entered the study subsequently received axillary radiotherapy. Patients 1 and 3 had Hodgkin’s lymphoma and patient 2 diffuse large B cell lymphoma; age range 21–70 years; mean pre-chemotherapy GTV 78 cm<sup>3</sup> (range 33–141). Each patient had received chemotherapy prior to planning for radiotherapy. Patient 1 had the diagnostic PET-CT scan arms down due to discomfort maintaining an arms-up position. (Fig. 1 provides an example of CTV<sub>INRT</sub> and CTV<sub>diagPET</sub> in axial and coronal images.)

4.1. Intra-observer variation in CTV generation

Intra-observer variation in delineating CTV<sub>INRT</sub> and CTV<sub>diagPET</sub> on 3 occasions for each patient are summarised in Table 1. Variation CTV extent was large for CTV<sub>diagPET</sub>, with a mean of 7 mm superiorly and 13 mm inferiorly. By contrast, CTV<sub>INRT</sub> varied by only a single CT slice (2–3 mm) superiorly and inferiorly. Similarly, CTV<sub>INRT</sub> was significantly more reproducible in the axial plane compared with CTV<sub>diagPET</sub> for all positional metrics.

4.2. Comparison of CTV<sub>INRT</sub> and CTV<sub>diagPET</sub>: Superior and inferior extent

Table 2 summarises CTV volumes and differences in the superior and inferior boundaries of CTV<sub>INRT</sub> and CTV<sub>diagPET</sub>. Overall vol-
umes were similar for patients 2 and 3, although CTV\textsubscript{diagPET} was larger for patient 1. For the superior CTV extent, CTV\textsubscript{diagPET} varied by +2 to 21 mm beyond CTV\textsubscript{INRT}. The inferior CTV extent, CTV\textsubscript{diagPET} varied by −27 to +12 mm. Based upon these data, there were considerable discrepancies between the superior and inferior extents of CTV\textsubscript{diagPET} and CTV\textsubscript{INRT}; for patient 2 an additional 27 mm was required inferiorly beyond CTV\textsubscript{diagPET} to ensure that CTV\textsubscript{INRT} was included.

4.3. Comparison of CTV\textsubscript{INRT} and CTV\textsubscript{diagPET}: Axial plane

Table 2 shows the positional metrics used to compare CTV\textsubscript{INRT} and CTV\textsubscript{diagPET} in the axial plane (data based on CTVs within overlapping lengths). Overall there was considerable differences between CTV\textsubscript{INRT} and CTV\textsubscript{diagPET} contours in the axial plane. Mean DICE index was limited at 0.63 (range 0.61–0.65). Mean differences in CGD was 5 mm (range 2.5–10.0). Mean Se.Idx was 0.68 (range

![Fig. 1. Comparison of cranio-caudal length of CTV\textsubscript{INRT} and CTV\textsubscript{diagPET} in the coronal plane in a patient with stage I diffuse large B cell lymphoma of left axilla treated with 3 cycles of chemotherapy followed by radiotherapy. In coronal plane A) represents pre-chemotherapy FDG PET-CT acquired in the routine arms up diagnostic position, B) represents pre-chemotherapy PET-CT in treatment position with a radiotherapy mask, C) planning CT scan with CTV\textsubscript{INRT} (blue) (contoured using co-registered pre-chemotherapy radiotherapy treatment-position PET-CT) and CTV\textsubscript{diagPET} (red) (contoured using side-by-side assessment of diagnostic PET-CT). In the axial plane D) and E) show pre-chemotherapy FDG PET-CT in arms up diagnostic position and treatment position arms down respectively, E) planning CT scan with CTV\textsubscript{INRT} (blue) and CTV\textsubscript{diagPET} (red). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image-url)
the CTV diagPET if an appropriate CTV expansion is not added to
extent was low for CTV INRT (maximum of 3 mm superior-inferior
reproducibility CTV contouring. Variation in the cranio-caudal CTV
for ISRT for axillary radiotherapy.

would assist in contouring the CTV diagPET, although it is notable
had the diagnostic PET-CT with arms down due to discomfort
required in the axial plane. One patient in this study (patient 1)
to anatomical boundaries and suggest a generous approach is
was 16.4 mm (mean 4 mm). These data are despite modification
account for this inaccuracy. The maximum MDC under coverage
was only limited conformity between CTV INRT and CTV diagPET in
CTVINRT and CTV diagPET volumes and their variation in superior and inferior extent.

0.63–0.79), indicating that a mean of 68% of CTV INRT was contained
within CTV diagPET in the axial plane. MDC includes both over- and
underlap of contours. Mean and maximum MDC undercoverage
(areas of undercoverage of CTV INRT by CTV diagPET) were 4 and
16.4 mm respectively. Mean and maximum MDC overcoverage
(regions of CTV diagPET which are non-overlapping with CTV INRT)
was 5.5 and 18.3 mm respectively.

5. Discussion

No previous studies have evaluated the CTV expansion required
for axillary radiotherapy. The treatment position FDC PET-CT in
this prospective study allows the generation of INRT CTVs which
represent a ‘gold standard’ for comparison with CTVs contoured
using non-registered diagnostic non-treatment position PET-CT.
This report aims to evaluate differences in CTV diagPET compared
with CTV INRT to inform on appropriate CTV margin expansions
for ISRT for axillary radiotherapy.

Intra-observer variability was assessed to provide a guide to the
reproducibility CTV contouring. Variation in the cranio-caudal CTV
extent was low for CTV INRT (maximum of 3 mm superior-inferior
variation) but higher for CTV diagPET (maximum 24 mm superiorly
and 12 mm inferiorly). Similarly, CTV INRT was significantly more
reproducible in the axial plane based on assessment of all posi-
tional metrics.

CTVINRT and CTV diagPET were compared in cranio-caudal extent
and in the axial plane. The maximum distance of ‘under-
contouring’ of the CTV diagPET compared with the ‘gold-standard’
CTVINRT was 27 mm inferiorly. The maximum ‘over-contouring’ of
the CTV diagPET was 21 mm superiorly and 15 mm inferiorly. There
was only limited conformity between CTV INRT and CTV diagPET in
the axial plane, with a mean DICE of 0.63 (range 0.61–0.65). The
mean Se.Idx was 0.68 (range 0.63–0.79) meaning that in the axial
plane a mean of 68% of the CTV INRT was encompassed by the
CTV diagPET, implying a significant risk of geographical miss with
the CTV diagPET if an appropriate CTV expansion is not added to
account for this inaccuracy. The maximum MDC under coverage
was 16.4 mm (mean 4 mm). These data are despite modification
to anatomical boundaries and suggest a generous approach is
required in the axial plane. One patient in this study (patient 1)
had the diagnostic PET-CT with arms down due to discomfort
maintaining the arms up position. It might be considered that this
would assist in contouring the CTV diagPET, although it is notable
that there remained considerable cranio-caudal differences and
similar positional metrics in the axial planes to the other two
patients.

These data indicate the potential inaccuracy of contouring an
axillary CTV in the absence of treatment-position PET-CT. As only
3 patients from our imaging study had axillary disease, this analy-
sis cannot explore the extent of variability in CTV contouring
between patients with small/large volume disease and different
sites within the axilla. However, analysis shows high intra-
observer variability, considerable cranio-caudal over- and under-
contouring, and limited conformity in the axial plane for
CTV diagPET. Contouring of CTV diagPET in patients with axillary disease
appears considerably less accurate than for neck disease based on
our prior data [6]. This is likely to relate to the large positional dif-
ferences between anatomy in the axilla depending upon arm posi-
tion and the lack of obvious anatomical landmarks by comparison
with the neck.

Our practice has been to deliver axillary radiotherapy arms
down with a 5-point thermoplastic mask which we have found
to optimise of reproducibility of shoulder/arm position and allow
simpler treatment of adjacent neck if required. Other treatment
positions are feasible e.g. arms up on a wing board which may offer
some separation of target volume from the lungs; this can match
the pre-chemotherapy arms up PET-CT position although unless
identical immobilisation devices are used positions will still differ.
Clearly these data cannot be directly applied to different treatment
positions. However, the variability shown highlights the impor-
tance attempting to obtain optimal treatment-position imaging
pre-chemotherapy. In the absence of optimal pre-chemotherapy
imaging clinical judgement is necessary in CTV construction based
upon ease in re-constructing the pre-chemotherapy extent of dis-
ease. These data demonstrate the difficulty of accurate tumour
reconstruction in the axilla and the need to carefully consider mar-
gins to avoid geographic misses.

In summary, our small cohort demonstrated that a generous
CTV expansion is required cranio-caudally and in the axial plane
to ensure the pre-chemotherapy extent of axillary disease is
encompassed. Centres should attempt to acquire pre-
chemotherapy PET-CT as close to the treatment position as pos-
sible to improve the accuracy of contouring and allow smaller CTVs.

Acknowledgements

We would like to acknowledge the assistance of Mrs Heather Hall
in identifying suitable patients for the study.

Funding source

The study was funded the The Leeds Teaching Hospitals Charitable
Foundation (Leeds Cares).

Conflicts of interest

We have no conflicts of interest to declare.

Table 2

CTVINRT and CTV diagPET volumes and their variation in superior and inferior extent.

| Patient | Variation in superior-inferior CTV extent | Comparison of CTVs in axial plane |
|---------|------------------------------------------|----------------------------------|
|         | Volume (cm³) | CoG (mm) (Sup-Inf direction) | Margins from CTV INRT to CTV diagPET (mm) | CI | MDC (mm) | CGD (mm) | DICE | Se.Idx |
|---------|--------------|-------------------------------|-------------------------------------|----|---------|---------|------|-------|
| 1       | 67           | 110                           | +66                                 | 2  | 12      | 0.40    | 9.74 | 0.63  |
| 2       | 109          | 114                           | +5                                  | 21 | -27     | 0.43    | 12.06 | 0.61  |
| 3       | 54           | 53                            | -2                                  | 12 | 0       | 0.48    | 6.43  | 0.65  |
| Mean    | 76           | 92                            | +21                                 | 9  | -2      | 0.44    | 9.41  | 0.63  |
| Stddev  | 34           | 29                            | -                                   | 6  | 15      | 0.04    | 2.83  | 0.68  |

CTV = clinical target volume; CoG = centre of gravity distance; CI = conformality index; MDC = mean distance to conformity; Se.Idx = sensitivity index.

* indicates undercontouring and ‘*’ indicates overcontouring over CTV diagPET compared with CTV INRT.
References

[1] Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270–7.

[2] Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–62.

[3] Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2014;89:49–58.

[4] Hoppe BS, Hoppe RT. Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015;92:40–5.

[5] Hoskin PJ, Diez P, Williams M, Lucraft H, Bayne M. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:49–58.

[6] Bird D, Patel C, Scarsbrook AF, et al. Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position. Radiother Oncol 2017;124:161–7.

[7] Jena R, Kirkby NF, Burton KE, Hoole AC, Tan LT, Burnet NG. A novel algorithm for the morphometric assessment of radiotherapy treatment planning volumes. Br J Radiol 2010;83:44–51.

[8] West BT. Linear mixed models: a practice guide using statistical software. 2nd ed. CRC Press; 2015.